Has Max Bowman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,206 in general payments to Max Bowman, MD across 42 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Max Bowman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Max Bowman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Max Bowman, MD

Urology · San Francisco, CANPI 1801391990

Payments from drug & device makers

$9,206in general payments, 2019–2025

Across 42 payments — averaging $219.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Calyxo, Inc.$5K
Boston Scientific$2K
Intuitive Surgical$1K
Urogen Pharma, Inc.$155
C. R. Bard, Inc. & Subsidiaries$122
Cook Medical LLC$114
plus $167 from 4 others

What the payments were for

Consulting fees$5,27557%
Travel & lodging$1,64918%
Food & beverage$2,28225%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Calyxo, Inc.	2	$5,275
Boston Scientific	26	$2,210
Intuitive Surgical	6	$1,163
Urogen Pharma, Inc.	1	$155
C. R. Bard, Inc. & Subsidiaries	1	$122
Cook Medical LLC	1	$114
Neotract Inc.	1	$79
Olympus America Inc.	1	$36
Procept Biorobotics Corporation	2	$32
Johnson & Johnson	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,206 in reported general payments places this provider in the 70th percentile of 1,324 urology providers in California.

See all urology providers in California →

Medicare billing

Part B allowed, 2024

$39,040

Medicare patients

214

Services billed

400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	35	$22,094
Finasteride	38	$596
Tamsulosin Hcl	43	$496
Alfuzosin Hcl ErAlfuzosin Hcl	13	$254

Paid to pharmacies, not to this prescriber.

Other urology in San Francisco

Marc Dall'eraSan Francisco$1.4M
Marshall StollerSan Francisco$898K
Peter CarrollSan Francisco$786K
Sima PortenSan Francisco$312K
Edward UchioOrange$21.1M
Stephen FreedlandWest Hollywood$16.7M
Alec KooTorrance$7.4M
Karim ChamieLos Angeles$4.3M
Ralph ClaymanOrange$3.9M
Siamak DaneshmandLos Angeles$3.5M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →